Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Hypertension

HemiClor
Regional

FDA Approves Low-Dose Hypertension Treatment HemiClor

May 12, 2025May 12, 2025 - by Timothy Alexander

WEST CONSHOHOCKEN, PA — The U.S. Food and Drug Administration (FDA) has approved HemiClor, a 12.5 mg chlorthalidone tablet developed by PRM Pharma, LLC, for the treatment of hypertension in …

FDA Approves Low-Dose Hypertension Treatment HemiClor Read More

Mineralys Therapeutics
Regional

Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM

April 28, 2025April 27, 2025 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the publication of groundbreaking Phase 2 trial results for its medication lorundrostat in the New England Journal of Medicine (NEJM). The …

Mineralys Therapeutics Publishes Pivotal Hypertension Trial Results in NEJM Read More
Idorsia
Regional

New Hypertension Treatment TRYVIO Now Available in the U.S.

November 19, 2024November 18, 2024 - by Timothy Alexander

RADNOR, PA — Idorsia Pharmaceuticals U.S. Inc. has announced the availability of TRYVIO™ (aprocitentan) in the United States for adults suffering from hypertension. This new medication is intended to be used …

New Hypertension Treatment TRYVIO Now Available in the U.S. Read More

Mineralys Therapeutics
Regional

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial

October 31, 2024October 30, 2024 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More
Mineralys Therapeutics
Regional

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances

October 24, 2024October 22, 2024 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced an upcoming virtual Key Opinion Leader (KOL) event scheduled for Wednesday, October 30, 2024, at 10:00 AM ET. This event will …

Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances Read More

Mineralys Therapeutics
Regional

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial

September 26, 2024September 25, 2024 - by Timothy Alexander

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has reached a significant milestone in its Advance-HTN trial by hitting its enrollment target of 261 participants. This pivotal trial is crucial in …

Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Drug Trial Read More

Posts pagination

Previous 1 2

Trending News

  • Rare Himalayan Blue Poppies Bloom Again at Longwood Gardens

  • Great Valley Students Raise Over $500 at Annual Desmond Project 3v3 Tournament

  • Vishay Precision Group to Present at March Investor Conferences

  • Ohio Contractor Accused of $80K Home-Improvement Fraud

  • Man Pleads Guilty in NCAA, CBA Basketball Game-Fixing Scheme

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Basketball

Great Valley Students Raise Over $500 at Annual Desmond Project 3v3 Tournament

5 hours agoMarch 10, 2026

Arrested

Ohio Contractor Accused of $80K Home-Improvement Fraud

11 hours agoMarch 10, 2026

Court News

Man Pleads Guilty in NCAA, CBA Basketball Game-Fixing Scheme

12 hours agoMarch 10, 2026

Copyright © 2026 MyChesCo.